Interpace Biosciences Reports 22% Revenue Drop, 56% Net Income Decline Amid Massive Dilution

summarizeSummary

Interpace Biosciences reported a significant 22% year-over-year revenue decrease and a 56% net income decline for Q1 2026, primarily due to the discontinuation of its PancraGEN test and substantial dilution from a preferred stock conversion.

check_boxKey Events

• Revenue Decline

  Net revenue decreased by 22% year-over-year to $9.0 million for Q1 2026, compared to $11.5 million in Q1 2025, primarily due to the discontinuation of the PancraGEN test.

• Profitability Drop

  Net income fell by 56% to $0.7 million for Q1 2026, and diluted EPS decreased by 50% to $0.03 per share, compared to $1.6 million and $0.06 respectively in Q1 2025.

• Massive Dilution from Preferred Stock Conversion

  All Series C Preferred Stock converted into approximately 23.3 million common shares in January 2026, increasing outstanding shares from 4.4 million to 27.7 million, a dilution of over 500%.

• Debt Elimination

  The company eliminated its note payable interest for Q1 2026, indicating the repayment of its former Term Loan.

auto_awesomeAnalysis

This quarterly report reveals a challenging financial period for Interpace Biosciences, marked by a substantial decline in revenue and net income. The primary driver for the revenue drop was the discontinuation of the PancraGEN test, a previously known issue. The most significant market-moving event is the massive dilution from the conversion of Series C Preferred Stock into 23.3 million common shares, which dramatically increased the outstanding share count and significantly impacted per-share metrics. While the company successfully eliminated its debt and projects sufficient liquidity for the near term, the severe dilution and ongoing revenue pressures present a negative outlook for existing shareholders. The company continues to pursue an uplisting to Nasdaq, which could improve capital-raising capabilities if successful.